142 related articles for article (PubMed ID: 16985587)
1. Finasteride and prostate cancer.
Khan MA; Partin AW
Rev Urol; 2004; 6(2):97-8. PubMed ID: 16985587
[No Abstract] [Full Text] [Related]
2. Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis.
Shepherd BE; Redman MW; Ankerst DP
J Am Stat Assoc; 2008 Dec; 103(484):1392-1404. PubMed ID: 20526381
[TBL] [Abstract][Full Text] [Related]
3. Association of finasteride with prostate cancer: A systematic review and meta-analysis.
Wang L; Lei Y; Gao Y; Cui D; Tang Q; Li R; Wang D; Chen Y; Zhang B; Wang H
Medicine (Baltimore); 2020 Apr; 99(15):e19486. PubMed ID: 32282699
[TBL] [Abstract][Full Text] [Related]
4. Finasteride.
Chaudhary UB; Turner JS
Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):873-81. PubMed ID: 20536414
[TBL] [Abstract][Full Text] [Related]
5. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk.
Irani J; Ravery V; Pariente JL; Chartier-Kastler E; Lechevallier E; Soulie M; Chautard D; Coloby P; Fontaine E; Bladou F; Desgrandchamps F; Haillot O
J Urol; 2002 Nov; 168(5):1985-8. PubMed ID: 12394690
[TBL] [Abstract][Full Text] [Related]
6. Does the level of prostate cancer risk affect cancer prevention with finasteride?
Thompson IM; Tangen CM; Parnes HL; Lippman SM; Coltman CA
Urology; 2008 May; 71(5):854-7. PubMed ID: 18455628
[TBL] [Abstract][Full Text] [Related]
7. New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer.
Ankerst DP; Thompson IM
Arch Ital Urol Androl; 2006 Dec; 78(4):154-6. PubMed ID: 17269622
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer prevention and finasteride.
D'Amico AV; Barry MJ
J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer risk among users of finasteride and alpha-blockers - a population based case-control study.
Murtola TJ; Tammela TL; Määttänen L; Hakama M; Auvinen A
Eur J Cancer; 2007 Mar; 43(4):775-81. PubMed ID: 17251005
[TBL] [Abstract][Full Text] [Related]
10. The clinical applications of five-alpha reductase inhibitors.
Loughlin KR
Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial.
Torkko K; Till C; Tangen CM; Goodman PJ; Song X; Schenk JM; Lucia MS; Peters U; van Bokhoven A; Thompson IM; Neuhouser ML
Cancer Prev Res (Phila); 2020 Jun; 13(6):521-530. PubMed ID: 32102946
[TBL] [Abstract][Full Text] [Related]
12. Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride.
Dai JY; LeBlanc M; Goodman PJ; Lucia MS; Thompson IM; Tangen CM
Cancer Prev Res (Phila); 2019 Feb; 12(2):113-120. PubMed ID: 30538099
[TBL] [Abstract][Full Text] [Related]
13. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.
Chu LW; Till C; Yang B; Tangen CM; Goodman PJ; Yu K; Zhu Y; Han S; Hoque AM; Ambrosone C; Thompson I; Leach R; Hsing AW
Mol Carcinog; 2018 Mar; 57(3):462-466. PubMed ID: 29318656
[TBL] [Abstract][Full Text] [Related]
14. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
Winchester DA; Till C; Goodman PJ; Tangen CM; Santella RM; Johnson-Pais TL; Leach RJ; Xu J; Zheng SL; Thompson IM; Lucia MS; Lippman SM; Parnes HL; Isaacs WB; De Marzo AM; Drake CG; Platz EA
Prostate; 2017 Jun; 77(8):908-919. PubMed ID: 28317149
[TBL] [Abstract][Full Text] [Related]
15. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.
Murtola TJ; Gurel B; Umbehr M; Lucia MS; Thompson IM; Goodman PJ; Kristal AR; Parnes HL; Lippman SM; Sutcliffe S; Peskoe SB; Barber JR; Drake CG; Nelson WG; De Marzo AM; Platz EA
Cancer Epidemiol Biomarkers Prev; 2016 Mar; 25(3):463-9. PubMed ID: 26715424
[TBL] [Abstract][Full Text] [Related]
16. Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Chau CH; Price DK; Till C; Goodman PJ; Chen X; Leach RJ; Johnson-Pais TL; Hsing AW; Hoque A; Tangen CM; Chu L; Parnes HL; Schenk JM; Reichardt JK; Thompson IM; Figg WD
PLoS One; 2015; 10(5):e0126672. PubMed ID: 25955319
[TBL] [Abstract][Full Text] [Related]
17. Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.
Hoque A; Yao S; Till C; Kristal AR; Goodman PJ; Hsing AW; Tangen CM; Platz EA; Stanczyk FZ; Reichardt JK; vanBokhoven A; Neuhouser ML; Santella RM; Figg WD; Price DK; Parnes HL; Lippman SM; Ambrosone CB; Thompson IM
Urology; 2015 Mar; 85(3):616-20. PubMed ID: 25733274
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival of participants in the prostate cancer prevention trial.
Thompson IM; Goodman PJ; Tangen CM; Parnes HL; Minasian LM; Godley PA; Lucia MS; Ford LG
N Engl J Med; 2013 Aug; 369(7):603-10. PubMed ID: 23944298
[TBL] [Abstract][Full Text] [Related]
19. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.
Yao S; Till C; Kristal AR; Goodman PJ; Hsing AW; Tangen CM; Platz EA; Stanczyk FZ; Reichardt JK; Tang L; Neuhouser ML; Santella RM; Figg WD; Price DK; Parnes HL; Lippman SM; Thompson IM; Ambrosone CB; Hoque A
Cancer Causes Control; 2011 Aug; 22(8):1121-31. PubMed ID: 21667068
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.
Murtola TJ; Tammela TL; Määttänen L; Ala-Opas M; Stenman UH; Auvinen A
Br J Cancer; 2009 Sep; 101(5):843-8. PubMed ID: 19654575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
